Cytosorbents (CTSO) Capital Expenditures (QoQ) (2011 - 2026)
Cytosorbents (CTSO) Capital Expenditures (QoQ) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn |
| 10 | Cytosorbents | 23.26 Mn | 18.85 Mn | 7.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.27% |
| Mar 31, 2026 | -89.81% |
| Dec 31, 2025 | 535.29% |
| Sep 30, 2025 | -54.05% |
| Jun 30, 2025 | 1,750.00% |
| Mar 31, 2025 | 100.97% |
| Dec 31, 2024 | -236.18% |
| Sep 30, 2024 | 753.50% |
| Jun 30, 2024 | -60.59% |
| Mar 31, 2024 | -91.60% |
| Dec 31, 2022 | -197.69% |
| Sep 30, 2022 | 1,274.84% |
| Jun 30, 2022 | -167.64% |
| Mar 31, 2022 | -80.49% |
| Dec 31, 2021 | 399.14% |
| Sep 30, 2021 | -254.35% |
| Jun 30, 2021 | 83.98% |
| Mar 31, 2021 | 164.58% |
| Dec 31, 2020 | -29.53% |
| Sep 30, 2020 | 183.94% |